Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Zagarella

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Clinical Pharmacology and Therapeutics|February 1, 1976
Spironolactone. I. Disposition and metabolismA Karim, J Zagarella, J Hribar, et al.
Clinical Pharmacology and Therapeutics|February 1, 1976
Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levelsA Karim, J Zagarella, T C Hutsell, et al.
Clinical Pharmacology and Therapeutics|September 1, 1973
Oxandrolone disposition and metabolism in manA Karim, R E Ranney, J Zagarella, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 1, 1978
Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dogA Karim, C Kook, R L Novotney, et al.
Clinical Pharmacology and Therapeutics|February 1, 1976
Spironolactone. II. BioavailabilityA Karim, J Zagarella, T C Hutsell, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 1, 1976
Species differences in the metabolism and disposition of spironolactoneA Karim, C Kook, D J Zitzewitz, et al.
Journal of Pharmaceutical Sciences|November 1, 1976
In vitro and in vivo availability of spironolactone from oral dosage formsA Y Chao, D R Sanvordeker, J Zagarella, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 1, 1977
Spironolactone: diversity in metabolic pathwaysA Karim, J Hribar, M Doherty, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Clinical Pharmacology and Therapeutics|February 1, 1976
Spironolactone. I. Disposition and metabolismA Karim, J Zagarella, J Hribar, et al.
Clinical Pharmacology and Therapeutics|February 1, 1976
Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levelsA Karim, J Zagarella, T C Hutsell, et al.
Clinical Pharmacology and Therapeutics|September 1, 1973
Oxandrolone disposition and metabolism in manA Karim, R E Ranney, J Zagarella, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 1, 1978
Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dogA Karim, C Kook, R L Novotney, et al.
Clinical Pharmacology and Therapeutics|February 1, 1976
Spironolactone. II. BioavailabilityA Karim, J Zagarella, T C Hutsell, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 1, 1976
Species differences in the metabolism and disposition of spironolactoneA Karim, C Kook, D J Zitzewitz, et al.
Journal of Pharmaceutical Sciences|November 1, 1976
In vitro and in vivo availability of spironolactone from oral dosage formsA Y Chao, D R Sanvordeker, J Zagarella, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 1, 1977
Spironolactone: diversity in metabolic pathwaysA Karim, J Hribar, M Doherty, et al.
Pageof 1